Linked Life Data

7486613

Source:http://linkedlifedata.com/resource/pubmed/id/7486613

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1995-12-6
pubmed:abstractText
Over fifty patients with severe head injury, and one hundred with stroke, have now been treated with the competitive NMDA antagonist CGS 19755 (selfotel). Preliminary analysis has shown possible evidence of benefit for both these clinical indications, and several other glutamate antagonists are now being evaluated for these indications in Phase II trials. The optimal dose of CGS 19755 (selfotel) for efficacy for severe head trauma has not yet been identified, but may be > 3 mg/kg, as at this dose there was evidence of an ICP lowering effect and improved CPP. For stroke, however, the maximal tolerated dose was 1.5 mg/kg, because these conscious patients developed hallucinations and agitation. There were no other significant drug-associated adverse events in either of these studies. It is difficult to determine the "neuroprotective" dose for this compound in humans. By extrapolating from animal studies the "best estimate" would be around 5 mg/kg in patients with severe head trauma. For stroke, behavioral side effects were the major limiting factor for dosing. Although several NMDA antagonists, including CGS 19755 (selfotel), are currently entering efficacy trials for stroke, based upon their tremendous potency in animal models, the problem of psychomimetic effects may necessitate the use of additional management strategies, e.g., more intensive monitoring and concomitant medications.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0077-8923
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
765
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
272-8; discussion 298
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies.
pubmed:affiliation
Division of Neurosurgery, School of Medicine, Medical College of Virginia, Richmond 23298-0631, USA.
pubmed:publicationType
Journal Article, Review